Alphatec Sees Q4 2025 Spine Device Sales Rise, Preps 3D Imaging Launch
Alphatec Holdings reported fourth-quarter 2025 revenue growth fueled by increased spine device sales and improved manufacturing efficiencies, narrowing its quarterly operating loss. Executives highlighted a planned 3D surgical imaging system launch in early 2026 and reaffirmed R&D spending priorities for the year.
1. Fourth-Quarter Results
Alphatec Holdings's fourth-quarter 2025 revenue rose year-over-year due to stronger spine device sales and improved manufacturing efficiency, which narrowed the operating loss compared to Q3. Adjusted EBITDA loss also contracted as gross margins improved on higher production volumes.
2. Pipeline and Outlook
Management detailed plans to launch a next-generation 3D surgical imaging system in early 2026 and reaffirmed prioritizing R&D investment across its spine instrumentation and biologics programs. Executives did not provide full-year guidance but emphasized disciplined capital allocation.